EE380 Cost-Effectiveness Analysis of Erlotinib Plus Bevacizumab As First-Line Therapy for Advanced EGFR Mutation-Positive Non-Squamous Non-Small Cell Lung Cancer in Japan
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.681
https://www.valueinhealthjournal.com/article/S1098-3015(23)00781-7/fulltext
Title :
EE380 Cost-Effectiveness Analysis of Erlotinib Plus Bevacizumab As First-Line Therapy for Advanced EGFR Mutation-Positive Non-Squamous Non-Small Cell Lung Cancer in Japan
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)00781-7&doi=10.1016/j.jval.2023.03.681
First page :
Section Title :
Open access? :
No
Section Order :
10158